全文获取类型
收费全文 | 73749篇 |
免费 | 8440篇 |
国内免费 | 4719篇 |
专业分类
耳鼻咽喉 | 810篇 |
儿科学 | 939篇 |
妇产科学 | 794篇 |
基础医学 | 7639篇 |
口腔科学 | 2123篇 |
临床医学 | 9209篇 |
内科学 | 9060篇 |
皮肤病学 | 813篇 |
神经病学 | 3319篇 |
特种医学 | 2745篇 |
外国民族医学 | 31篇 |
外科学 | 8025篇 |
综合类 | 14883篇 |
现状与发展 | 22篇 |
一般理论 | 7篇 |
预防医学 | 5984篇 |
眼科学 | 1802篇 |
药学 | 8125篇 |
111篇 | |
中国医学 | 5087篇 |
肿瘤学 | 5380篇 |
出版年
2024年 | 213篇 |
2023年 | 1114篇 |
2022年 | 2389篇 |
2021年 | 4082篇 |
2020年 | 3326篇 |
2019年 | 2622篇 |
2018年 | 2631篇 |
2017年 | 2766篇 |
2016年 | 2462篇 |
2015年 | 3830篇 |
2014年 | 4729篇 |
2013年 | 4764篇 |
2012年 | 6898篇 |
2011年 | 7216篇 |
2010年 | 5343篇 |
2009年 | 4406篇 |
2008年 | 5020篇 |
2007年 | 4454篇 |
2006年 | 3995篇 |
2005年 | 3299篇 |
2004年 | 2272篇 |
2003年 | 1841篇 |
2002年 | 1423篇 |
2001年 | 1060篇 |
2000年 | 972篇 |
1999年 | 768篇 |
1998年 | 428篇 |
1997年 | 401篇 |
1996年 | 332篇 |
1995年 | 260篇 |
1994年 | 221篇 |
1993年 | 189篇 |
1992年 | 179篇 |
1991年 | 172篇 |
1990年 | 170篇 |
1989年 | 135篇 |
1988年 | 107篇 |
1987年 | 91篇 |
1986年 | 72篇 |
1985年 | 50篇 |
1984年 | 31篇 |
1983年 | 24篇 |
1982年 | 14篇 |
1981年 | 19篇 |
1980年 | 18篇 |
1979年 | 17篇 |
1978年 | 12篇 |
1977年 | 14篇 |
1975年 | 9篇 |
1974年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
42.
目的:统计分析中国县级及以上医疗机构青光眼亚专科建设、诊疗设备配备和服务提供情况,为进 一步推动我国青光眼防治工作提供理论依据。方法:调查研究。2015年对全国提供眼科服务的县级 及以上医疗机构通过网上填报的方式进行普查,采用描述性统计方法,对我国县级及以上医疗机构 青光眼亚专科建设、诊疗设备配备和服务提供情况进行系统整理和统计分析。结果:本次调查覆盖 全国6 341家县级及以上医疗机构,其中设立青光眼亚专科的医疗机构有672家(10.60%)。在青光眼 检查和治疗相关设备中,视力表配置率最高(99.30%),平均每家医疗机构配置3.28台;超声生物显 微镜配置率最低(11.50%),平均每家医疗机构配置0.13台。眼压测量、白内障手术和小梁切开术是 青光眼主要的诊疗服务类型。结论:我国县级及以上医疗机构青光眼亚专科建设亟待加强,诊疗设 备配备不全,诊疗服务能力需要全面提升。 相似文献
43.
44.
45.
46.
Algorithms based on deep neural networks (DNNs) have attracted increasing attention from the scientific computing community. DNN based algorithms are
easy to implement, natural for nonlinear problems, and have shown great potential to
overcome the curse of dimensionality. In this work, we utilize the multi-scale DNN-based algorithm (MscaleDNN) proposed by Liu, Cai and Xu (2020) to solve multi-scale
elliptic problems with possible nonlinearity, for example, the p-Laplacian problem.
We improve the MscaleDNN algorithm by a smooth and localized activation function.
Several numerical examples of multi-scale elliptic problems with separable or non-separable scales in low-dimensional and high-dimensional Euclidean spaces are used
to demonstrate the effectiveness and accuracy of the MscaleDNN numerical scheme. 相似文献
47.
48.
目的调查嘉兴市新居民儿童心理发育行为问题及影响因素,为改善新居民儿童心理健康提供理论依据。方法随机抽取新居民儿童548例,本地儿童1248例,采用自编量表评估儿童家庭影响因素,长处与困难问卷评估儿童心理发育行为问题,心理痛苦温度计评估主观心理痛苦程度,儿童心理虐待与忽视量表评估家庭教养方式,社会支持量表评估社会支持程度。结果新居民儿童主观评定心理痛苦程度高于本地儿童(P=0.002)。新居民儿童亲社会化行为低于本地儿童(P=0.000),多动/注意缺陷问题高于本地儿童(P=0.011)。儿童忽视虐待量表本地儿童5个因子得分低于新居民儿童:责骂因子(P=0.000)、恐吓因子(P=0.000)、情感忽视因子(P=0.000)、教育忽视因子(P=0.000)、身体忽视因子(P=0.000)。社会支持量表本地儿童3个因子得分均高于新居民儿童:客观支持(P=0.032)、主观支持(P=0.000)、对支持的利用度(P=0.000)。新居民儿童在新居民儿童学校、混合学校、本地儿童学校的3类学校中亲社会化行为、忽视因子、虐待因子、社会支持均有统计学差异(均P<0.05)。结论新居民儿童较本地儿童心理发育行为明显落后,良好的家庭教养方式和有效的社会支持系统能够更快更好地促进其身心发育。 相似文献
49.
目的:探讨Ki-67表达与原发性肝癌根治性切除术后行预防性TACE患者预后的关系。方法:采用回顾性队列研究,收集2014年12月—2016年1月福建医科大学孟超肝胆医院150例行原发性肝癌根治性切除术并在术后2个月内行预防性TACE患者的临床病理资料,根据术后肝癌组织病理Ki-67评分分为为低表达组(Ki-67评分≤20%,44例)和高表达组(Ki-67评分20%,106例);分析Ki-67表达量与患者临床病理因素及复发与生存的关系。结果:高表达组肿瘤多发、肿瘤包膜不完整及合并微血管癌栓患者比例明显高于低表达组(均P0.05)。Ki-67高表达与肿瘤多发、肿瘤直径大为影响无瘤生存期的独立危险因素(均P0.05);Ki-67高表达与肿瘤多发、肿瘤直径大、肿瘤包膜不完整、合并微血管癌栓为影响总生存期的独立危险因素(均P0.05);高表达组患者复发率明显高于低表达组(57.9%vs. 37.7%,χ~2=6.777,P0.05),总生存率明显低于低表达组(45.6%vs. 75.9%,χ~2=8.447,P0.05)。结论:Ki-67的表达量对肝癌根治性切除术后行预防性TACE患者的预后有显著影响,高表达者预后不良。 相似文献
50.
Se-Jin Lee Adam Lehar Yewei Liu Chi Hai Ly Quynh-Mai Pham Michael Michaud Renata Rydzik Daniel W. Youngstrom Michael M. Shen Vesa Kaartinen Emily L. Germain-Lee Thomas A. Rando 《Proceedings of the National Academy of Sciences of the United States of America》2020,117(49):30907
Myostatin (MSTN) is a transforming growth factor-β (TGF-β) family member that normally acts to limit muscle growth. The function of MSTN is partially redundant with that of another TGF-β family member, activin A. MSTN and activin A are capable of signaling through a complex of type II and type I receptors. Here, we investigated the roles of two type II receptors (ACVR2 and ACVR2B) and two type I receptors (ALK4 and ALK5) in the regulation of muscle mass by these ligands by genetically targeting these receptors either alone or in combination specifically in myofibers in mice. We show that targeting signaling in myofibers is sufficient to cause significant increases in muscle mass, showing that myofibers are the direct target for signaling by these ligands in the regulation of muscle growth. Moreover, we show that there is functional redundancy between the two type II receptors as well as between the two type I receptors and that all four type II/type I receptor combinations are utilized in vivo. Targeting signaling specifically in myofibers also led to reductions in overall body fat content and improved glucose metabolism in mice fed either regular chow or a high-fat diet, demonstrating that these metabolic effects are the result of enhanced muscling. We observed no effect, however, on either bone density or muscle regeneration in mice in which signaling was targeted in myofibers. The latter finding implies that MSTN likely signals to other cells, such as satellite cells, in addition to myofibers to regulate muscle homeostasis.Myostatin (MSTN) is a secreted signaling molecule that normally acts to limit skeletal muscle growth (for review, see ref. 1). Mice lacking MSTN exhibit dramatic increases in muscle mass throughout the body, with individual muscles growing to about twice the normal size (2). MSTN appears to play two distinct roles in regulating muscle size, one to regulate the number of muscle fibers that are formed during development and a second to regulate the growth of those fibers postnatally. The sequence of MSTN has been highly conserved through evolution, with the mature MSTN peptide being identical in species as divergent as humans and turkeys (3). The function of MSTN has also been conserved, and targeted or naturally occurring mutations in MSTN have been shown to cause increased muscling in numerous species, including cattle (3–5), sheep (6), dogs (7), rabbits (8), rats (9), swine (10), goats (11), and humans (12). Numerous pharmaceutical and biotechnology companies have developed biologic agents capable of blocking MSTN activity, and these have been tested in clinical trials for a wide range of indications, including Duchenne and facioscapulohumeral muscular dystrophy, inclusion body myositis, muscle atrophy following falls and hip fracture surgery, age-related sarcopenia, Charcot–Marie–Tooth disease, and cachexia due to chronic obstructive pulmonary disease, end-stage kidney disease, and cancer.The finding that certain inhibitors of MSTN signaling can increase muscle mass even in Mstn−/− mice revealed that the function of MSTN as a negative regulator of muscle mass is partially redundant with at least one other TGF-β family member (13, 14), and subsequent studies have identified activin A as one of these cooperating ligands (15, 16). MSTN and activin A share many key regulatory and signaling components. For example, the activities of both MSTN and activin A can be modulated extracellularly by naturally occurring inhibitory binding proteins, including follistatin (17, 18) and the follistatin-related protein, FSTL-3 or FLRG (19, 20). Moreover, MSTN and activin A also appear to share receptor components. Based on in vitro studies, MSTN is capable of binding initially to the activin type II receptors, ACVR2 and ACVR2B (also called ActRIIA and ActRIIB) (18) followed by engagement of the type I receptors, ALK4 and ALK5 (21). In previous studies, we presented genetic evidence supporting a role for both ACVR2 and ACVR2B in mediating MSTN signaling and regulating muscle mass in vivo. Specifically, we showed that mice expressing a truncated, dominant-negative form of ACVR2B in skeletal muscle (18) or carrying deletion mutations in Acvr2 and/or Acvr2b (13) have significantly increased muscle mass. One limitation of the latter study, however, was that we could not examine the consequence of complete loss of both receptors using the deletion alleles, as double homozygous mutants die early during embryogenesis (22). Moreover, the roles that the two type I receptors, ALK4 and ALK5, play in regulating MSTN and activin A signaling in muscle in vivo have not yet been documented using genetic approaches. Here, we present the results of studies in which we used floxed alleles for each of the type II and type I receptor genes in order to target these receptors alone and in combination in muscle fibers. We show that these receptors are functionally redundant and that signaling through each of these receptors contributes to the overall control of muscle mass. 相似文献